Clinical characteristics of pediatric patients with IBD who received COVID vaccination.
| Clinical Characteristic . | Vaccination +/- Prior Infection . |
|---|---|
| . | n = 20 . |
| Demographics | |
| Male, N (%) | 12 (60) |
| Age (years), Median (IQR) | 18 (17–20) |
| Vaccination Type | |
| BNT162b2 (Pfizer-BioNTech) | 14 (70) |
| mRNA-1273 (NIH-Moderna) | 5 (25) |
| JNJ-78436735 (Johnson & Johnson) | 1 (5) |
| IBD Subtype, N (%) | |
| Crohn’s Disease | 15 (75) |
| Ulcerative colitis | 5 (25) |
| Age of Diagnosis, N (%) | |
| Diagnosis <17 years | 17 (85) |
| Crohn’s Disease Location | |
| Ileal | 4 (29) |
| Colonic | 1 (7) |
| Ileocolonic | 8 (57) |
| Isolated Upper Tract | 1 (7) |
| Crohn’s Disease Behavior, N (%) | |
| Non-penetrating, nonstricturing | 11 (85) |
| Stricturing | 1 (8) |
| Penetrating | 0 (0) |
| Stricturing and Penetrating | 1 (8) |
| Perianal Disease | 2 (15) |
| Ulcerative Colitis/IBD-U, N (%) | |
| Proctitis | 0 (0) |
| Left-sided | 1 (20) |
| Extensive/pancolitis | 4 (80) |
| IBD Therapy, N (%) (Supplementary Figure 1B) | |
| Biologic Therapy | 19 (95) |
| Infliximab | 7 (37) |
| Adalimumab | 2 (11) |
| Ustekinumab | 10 (53) |
| Vedolizumab | 0 (0) |
| Tofacitinib | 2 (10)c |
| Disease Activity, N (%) | |
| Clinical remissiona at time of vaccination | 17 (89) |
| SARS-CoV-2 Antibody Testing | |
| Antibody positive, N (%) | 20 (100) |
| Median (IQR) time from last vaccination to titer (days) | 29 (14–37)b |
| High titer, N (%) | 18 (95)b |
| History of Infection, N (%) | 5 (25) |
| Clinical Characteristic . | Vaccination +/- Prior Infection . |
|---|---|
| . | n = 20 . |
| Demographics | |
| Male, N (%) | 12 (60) |
| Age (years), Median (IQR) | 18 (17–20) |
| Vaccination Type | |
| BNT162b2 (Pfizer-BioNTech) | 14 (70) |
| mRNA-1273 (NIH-Moderna) | 5 (25) |
| JNJ-78436735 (Johnson & Johnson) | 1 (5) |
| IBD Subtype, N (%) | |
| Crohn’s Disease | 15 (75) |
| Ulcerative colitis | 5 (25) |
| Age of Diagnosis, N (%) | |
| Diagnosis <17 years | 17 (85) |
| Crohn’s Disease Location | |
| Ileal | 4 (29) |
| Colonic | 1 (7) |
| Ileocolonic | 8 (57) |
| Isolated Upper Tract | 1 (7) |
| Crohn’s Disease Behavior, N (%) | |
| Non-penetrating, nonstricturing | 11 (85) |
| Stricturing | 1 (8) |
| Penetrating | 0 (0) |
| Stricturing and Penetrating | 1 (8) |
| Perianal Disease | 2 (15) |
| Ulcerative Colitis/IBD-U, N (%) | |
| Proctitis | 0 (0) |
| Left-sided | 1 (20) |
| Extensive/pancolitis | 4 (80) |
| IBD Therapy, N (%) (Supplementary Figure 1B) | |
| Biologic Therapy | 19 (95) |
| Infliximab | 7 (37) |
| Adalimumab | 2 (11) |
| Ustekinumab | 10 (53) |
| Vedolizumab | 0 (0) |
| Tofacitinib | 2 (10)c |
| Disease Activity, N (%) | |
| Clinical remissiona at time of vaccination | 17 (89) |
| SARS-CoV-2 Antibody Testing | |
| Antibody positive, N (%) | 20 (100) |
| Median (IQR) time from last vaccination to titer (days) | 29 (14–37)b |
| High titer, N (%) | 18 (95)b |
| History of Infection, N (%) | 5 (25) |
aClinical remission: partial Mayo Score <2 or Harvey-Bradshaw Index <4
bSingle patient with qualitative titer only available
cOne patient was on combination ustekinumab and tofacitinib
Clinical characteristics of pediatric patients with IBD who received COVID vaccination.
| Clinical Characteristic . | Vaccination +/- Prior Infection . |
|---|---|
| . | n = 20 . |
| Demographics | |
| Male, N (%) | 12 (60) |
| Age (years), Median (IQR) | 18 (17–20) |
| Vaccination Type | |
| BNT162b2 (Pfizer-BioNTech) | 14 (70) |
| mRNA-1273 (NIH-Moderna) | 5 (25) |
| JNJ-78436735 (Johnson & Johnson) | 1 (5) |
| IBD Subtype, N (%) | |
| Crohn’s Disease | 15 (75) |
| Ulcerative colitis | 5 (25) |
| Age of Diagnosis, N (%) | |
| Diagnosis <17 years | 17 (85) |
| Crohn’s Disease Location | |
| Ileal | 4 (29) |
| Colonic | 1 (7) |
| Ileocolonic | 8 (57) |
| Isolated Upper Tract | 1 (7) |
| Crohn’s Disease Behavior, N (%) | |
| Non-penetrating, nonstricturing | 11 (85) |
| Stricturing | 1 (8) |
| Penetrating | 0 (0) |
| Stricturing and Penetrating | 1 (8) |
| Perianal Disease | 2 (15) |
| Ulcerative Colitis/IBD-U, N (%) | |
| Proctitis | 0 (0) |
| Left-sided | 1 (20) |
| Extensive/pancolitis | 4 (80) |
| IBD Therapy, N (%) (Supplementary Figure 1B) | |
| Biologic Therapy | 19 (95) |
| Infliximab | 7 (37) |
| Adalimumab | 2 (11) |
| Ustekinumab | 10 (53) |
| Vedolizumab | 0 (0) |
| Tofacitinib | 2 (10)c |
| Disease Activity, N (%) | |
| Clinical remissiona at time of vaccination | 17 (89) |
| SARS-CoV-2 Antibody Testing | |
| Antibody positive, N (%) | 20 (100) |
| Median (IQR) time from last vaccination to titer (days) | 29 (14–37)b |
| High titer, N (%) | 18 (95)b |
| History of Infection, N (%) | 5 (25) |
| Clinical Characteristic . | Vaccination +/- Prior Infection . |
|---|---|
| . | n = 20 . |
| Demographics | |
| Male, N (%) | 12 (60) |
| Age (years), Median (IQR) | 18 (17–20) |
| Vaccination Type | |
| BNT162b2 (Pfizer-BioNTech) | 14 (70) |
| mRNA-1273 (NIH-Moderna) | 5 (25) |
| JNJ-78436735 (Johnson & Johnson) | 1 (5) |
| IBD Subtype, N (%) | |
| Crohn’s Disease | 15 (75) |
| Ulcerative colitis | 5 (25) |
| Age of Diagnosis, N (%) | |
| Diagnosis <17 years | 17 (85) |
| Crohn’s Disease Location | |
| Ileal | 4 (29) |
| Colonic | 1 (7) |
| Ileocolonic | 8 (57) |
| Isolated Upper Tract | 1 (7) |
| Crohn’s Disease Behavior, N (%) | |
| Non-penetrating, nonstricturing | 11 (85) |
| Stricturing | 1 (8) |
| Penetrating | 0 (0) |
| Stricturing and Penetrating | 1 (8) |
| Perianal Disease | 2 (15) |
| Ulcerative Colitis/IBD-U, N (%) | |
| Proctitis | 0 (0) |
| Left-sided | 1 (20) |
| Extensive/pancolitis | 4 (80) |
| IBD Therapy, N (%) (Supplementary Figure 1B) | |
| Biologic Therapy | 19 (95) |
| Infliximab | 7 (37) |
| Adalimumab | 2 (11) |
| Ustekinumab | 10 (53) |
| Vedolizumab | 0 (0) |
| Tofacitinib | 2 (10)c |
| Disease Activity, N (%) | |
| Clinical remissiona at time of vaccination | 17 (89) |
| SARS-CoV-2 Antibody Testing | |
| Antibody positive, N (%) | 20 (100) |
| Median (IQR) time from last vaccination to titer (days) | 29 (14–37)b |
| High titer, N (%) | 18 (95)b |
| History of Infection, N (%) | 5 (25) |
aClinical remission: partial Mayo Score <2 or Harvey-Bradshaw Index <4
bSingle patient with qualitative titer only available
cOne patient was on combination ustekinumab and tofacitinib
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
